screening for residual disease in pediatric burkitt lymphoma using consensus primer pools筛查残留病在儿科伯基特淋巴瘤使用共识底漆池.pdf

Hindawi Publishing Corporation Advances in Hematology Volume 2009, Article ID 412163, 7 pages doi:10.1155/2009/412163 Research Article Screening for Residual Disease in Pediatric Burkitt Lymphoma Using Consensus Primer Pools Melissa Agsalda,1 Ian Kusao,2 David Troelstrup,3 and Bruce Shiramizu3 1 Department of Cell Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96816, USA 2 Department of Physiology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96816, USA 3 Department of Pediatrics Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96816, USA Correspondence should be addressed to Bruce Shiramizu, bshirami@ Received 30 December 2008; Accepted 25 January 2009 Recommended by Thomas G. Gross Assessing molecular persistent or minimal residual disease (PD/MRD) in childhood Burkitt lymphoma (BL) is challenging because access to original tumor is usually needed to design patient-specific primers (PSPs). Because BL is characterized by rearranged immunoglobulin heavy chain (IgVH ) genes, IgVH primer pools from IgVH1–IgVH7 regions were tested to detect PD/MRD, thus eliminating the need for original tumor. The focus of the current study was to assess the feasibility of using IgVH primer pools to detect disease in clinical specimens. Fourteen children diagnosed with B-NHL had follow-up repository specimens available to assess PD/MRD. Of the 14 patients, 12 were PD/MRD negative after 2 months of therapy and remained in remission at the end of therapy; 2/14 patients were PD/MRD positive at 2-3 months and later relapsed. PSP-based assays from these 14 patients showed 100% concordance with the current assay. This feasibility study warrants further investigation to assess PD/MRD using